Graft-versus-host disease is the major determinant of humoral responses to the AS03-adjuvanted influenza A/09/H1N1 vaccine in allogeneic hematopoietic stem cell transplant recipients

Haematologica

Volumn 96, Issue 6, 2011, Pages 896-904

  Mohty, Bilal ^a   Bel, Michael ^a   Vukicevic, Marija ^a   Nagy, Monika ^a   Levrat, Emmanuel ^a   Meier, Sara ^a   Grillet, Stephane ^a   Combescure, Christophe ^a   Kaiser, Laurent ^a   Chalandon, Yves ^a   Passweg, Jakob ^a   Siegrist, Claire Anne ^a   Roosnek, Eddy ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Allogeneic hematopoietic stem cell transplantation; Antibodies; GvHD; Influenza a (H1N1); Swine flu; Vaccination

Indexed keywords

AS 03; CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CYCLOSPORIN A; HEMOGLOBIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS; UNCLASSIFIED DRUG;

ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANOREXIA; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CD4 LYMPHOCYTE COUNT; CHILL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; GRAFT VERSUS HOST REACTION; HEMAGGLUTINATION INHIBITION TEST; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMORAL IMMUNITY; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; INFLUENZA A (H1N1); INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE SWELLING; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MYALGIA; NAUSEA; OPEN STUDY; PROSPECTIVE STUDY; SEROCONVERSION; SIDE EFFECT;

ADULT; AGED; ANTIBODIES, VIRAL; ANTIBODY FORMATION; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNITY, HUMORAL; IMMUNIZATION; IMMUNOCOMPROMISED HOST; INFLUENZA VACCINES; MALE; MIDDLE AGED; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 79958036690     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2011.040386     Document Type: Article

References (45)

1. Martino R, Porras RP, Rabella N, Williams JV, Ramila E, Margall N, et al. Prospective study of the incidence, clinical features, and outcome of symptomatic upper and lower respiratory tract infections by respiratory viruses in adult recipients of hematopoietic stem cell transplants for hematologic malignancies. Biol Blood Marrow Transplant. 2005;11(10):781-96.
2. Ljungman P, Ward KN, Crooks BN, Parker A, Martino R, Shaw PJ, et al. Respiratory virus infections after stem cell transplantation: a prospective study from theInfectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 2001;28(5):479-84.
3. Nichols WG, Guthrie KA, Corey L, Boeckh M. Influenza infections after hematopoietic stem cell transplantation: risk factors, mortality, and the effect of antiviral therapy. Clin Infect Dis. 2004;39(9):1300-6.
4. Khanna N, Steffen I, Studt JD, Schreiber A, Lehmann T, Weisser M, et al. Outcome of influenza infections in outpatients after allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis. 2009;11(2): 100-5.
5. Martino R, Ramila E, Rabella N, Munoz JM, Peyret M, Portos JM, et al. Respiratory virus infections in adults with hematologic malignancies: a prospective study. Clin Infect Dis. 2003;36(1):1-8.
6. Ljungman P, Avetisyan G. Influenza vaccination in hematopoietic SCT recipients. Bone Marrow Transplant. 2008;42(10):637-41.
7. Machado CM, Cardoso MR, da Rocha IF, Boas LS, Dulley FL, Pannuti CS. The benefit of influenza vaccination after bone marrow transplantation. Bone Marrow Transplant. 2005;36(10):897-900.
8. Garten RJ, Davis CT, Russell CA, Shu B, Lindstrom S, Balish A, et al. Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science. 2009;325(5937):197-201.
9. CDC. Outbreak of swine-origin influenza A (H1N1) virus infection - Mexico, March-April 2009. MMWR Morb Mortal Wkly Rep. 2009;58(17):467-70.
10. Bautista E, Chotpitayasunondh T, Gao Z, Harper SA, Shaw M, Uyeki TM, et al. Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. N Engl J Med. 2010;362(18):1708-19.
11. EMEA. European Medicines Agency pandemic influenza (H1N1) website. [cited 2010, Dec. 12]; Available from: www.ema.europa.eu/influenza/home.htm
12. EMEA. European Medicines Agency recommends authorisation of two vaccines for influenza pandemic (H1N1) 2009. [cited 2010, december 12]; The European Agency for the Evaluation of Medicinal Products]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2009/12/WC500018421.pdf
13. Lambert LC, Fauci AS. Influenza vaccines for the future. N Engl J Med. 2010;363(21): 2036-44.
14. European Medicines Agency. Summary of product characteristics. [Available from: http://www.ema.europa.eu/
15. Kendal AP, Pereira MS, Skehel JJ. Concepts and procedures for laboratory-based influenza surveillances. Atlanta, Georgia, 1982.
16. Miller E, Hoschler K, Hardelid P, Stanford E, Andrews N, Zambon M. Incidence of 2009 pandemic influenza A H1N1 infection in England: a cross-sectional serological study. Lancet. 2010;375(9720):1100-8.
17. Hosaka Y, Hosokawa Y. Purification of Sendai virions with glutaraldehyde-treated red blood cells. Intervirology. 1977;8(1):1-17.
18. Ikram H, Prince AM. A method for coupling cytomegalovirus antigens to aldehyde-fixed erythrocytes for use in passive hemagglutination. J Virol Methods. 1983;7 (3):127-34.
19. Reed GF, Meade BD, Steinhoff MC. Thereverse cumulative distribution plot: a graphic method for exploratory analysis of antibody data. Pediatrics. 1995;96(3 Pt2):600-3.
20. Mohty B, Thomas Y, Vukicevic M, Nagy M, Levrat E, Bernimoulin M, et al. Clinical features and outcome of 2009-influenza A (H1N1) after allogeneic hematopoietic stem cell transplantation. Bone Marrow Trans -plant. 2011 Mar 21. [Epub ahead of print]
21. Avetisyan G, Aschan J, Hassan M, Ljung -man P. Evaluation of immune responses to seasonal influenza vaccination in healthy volunteers and in patients after stem cell transplantation. Transplantation. 2008;86 (2):257-63.
22. de Lavallade H, Garland P, Sekine T, Hoschler K, Marin D, Stringaris K, et al. Repeated vaccination is required to optimize seroprotection against H1N1 in the immunocompromised host. Haematologica. 2011;96(2):307-14.
23. Engelhard D, Nagler A, Hardan I, Morag A, Aker M, Baciu H, et al. Antibody response to a two-dose regimen of influenza vaccine in allogeneic T cell-depleted and autologous BMT recipients. Bone Marrow Transplant. 1993;11(1):1-5.
24. Ljungman P, Nahi H, Linde A. Vaccination of patients with haematological malignancies with one or two doses of influenza vaccine: a randomised study. Br J Haematol. 2005;130(1):96-8.
25. Pauksen K, Linde A, Hammarstrom V, Sjolin J, Carneskog J, Jonsson G, et al. Gra - nulocyte-macrophage colony-stimulating factor as immunomodulating factor together with influenza vaccination in stem cell transplant patients. Clin Infect Dis. 2000;30 (2):342-8.
26. Kunisaki KM, Janoff EN. Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses. Lancet Infect Dis. 2009;9(8):493-504.
27. Hancock K, Veguilla V, Lu X, Zhong W, Butler EN, Sun H, et al. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med. 2009; 361(20):1945-52.
28. Wei CJ, Boyington JC, McTamney PM, Kong WP, Pearce MB, Xu L, et al. Induction of broadly neutralizing H1N1 influenza antibodies by vaccination. Science. 2010; 329(5995):1060-4.
29. Brydak LB, Calbecka M. Immunogenicity of influenza vaccine in patients with hemato- oncological disorders. Leuk Lymphoma. 1999;32(3-4):369-74.
30. Lo W, Whimbey E, Elting L, Couch R, Cabanillas F, Bodey G. Antibody response to a two-dose influenza vaccine regimen in adult lymphoma patients on chemotherapy. Eur J Clin Microbiol Infect Dis. 1993; 12(10):778-82.
31. Ljungman P, Cordonnier C, Einsele H, Englund J, Machado CM, Storek J, et al. Vaccination of hematopoietic cell transplant recipients. Bone Marrow Transplant. 2009;44(8):521-6.
32. Issa NC, Marty FM, Gagne LS, Koo S, Verrill KA, Alyea EP, et al. Seroprotective titers against 2009 H1N1 influenza A virus after vaccination in allogeneic hematopoietic stem cell transplantation recipients. Biol Blood Marrow Transplant. 2010;17(3): 434-8.
33. Ditschkowski M, Elmaagacli AH, Beelen DW. H1N1 in allogeneic stem cell recipients: courses of infection and influence of vaccination on graft-versus-host-disease (GVHD). Ann Hematol. 2010;90(1):117-8.
34. Haining WN, Evans JW, Seth NP, Callaway GD, Wucherpfennig KW, Nadler LM, et al. Measuring T cell immunity to influenza vaccination in children after haemopoietic stem cell transplantation. Br J Haematol. 2004;127(3):322-5.
35. Gandhi MK, Egner W, Sizer L, Inman I, Zambon M, Craig JI, et al. Antibody responses to vaccinations given within the first two years after transplant are similar between autologous peripheral blood stem cell and bone marrow transplant recipients. Bone Marrow Transplant. 2001;28(8):775-81.
36. Maris M, Boeckh M, Storer B, Dawson M, White K, Keng M, et al. Immunologic recovery after hematopoietic cell transplantation with nonmyeloablative conditioning. Exp Hematol. 2003;31(10):941-52.
37. Ademokun A, Wu YC, Dunn-Walters D. The ageing B cell population: composition and function. Biogerontology. 2010;11(2): 125-37.
38. Grubeck-Loebenstein B, Della Bella S, Iorio AM, Michel JP, Pawelec G, Solana R. Immunosenescence and vaccine failure in the elderly. Aging Clin Exp Res. 2009;21(3): 201-9.
39. Panda A, Arjona A, Sapey E, Bai F, Fikrig E, Montgomery RR, et al. Human innate immunosenescence: causes and consequences for immunity in old age. Trends Immunol. 2009;30(7):325-33.
40. Storek J, Witherspoon RP, Luthy D, Storb R. Low IgG production by mononuclear cells from marrow transplant survivors and from normal neonates is due to a defect of B cells. Bone Marrow Transplant. 1995;15(5): 679-84.
41. Manz RA, Thiel A, Radbruch A. Lifetime of plasma cells in the bone marrow. Nature. 1997;388(6638):133-4.
42. Gerritsen EJ, van Tol MJ, Lankester AC, van der Weijden-Ragas CP, Jol-van der Zijde CM, Oudeman-Gruber NJ, et al. Immuno -globulin levels and monoclonal gammopathies in children after bone marrow transplantation. Blood. 1993;82(11): 3493-502.
43. Roux E, Dumont-Girard F, Starobinski M, Siegrist CA, Helg C, Chapuis B, et al. Recovery of immune reactivity after T-celldepleted bone marrow transplantation depends on thymic activity. Blood. 2000;96 (6):2299-303.
44. Weinberg K, Blazar BR, Wagner JE, Agura E, Hill BJ, Smogorzewska M, et al. Factors affecting thymic function after allogeneic hematopoietic stem cell transplantation. Blood. 2001;97(5):1458-66.
45. Storek J, Geddes M, Khan F, Huard B, Helg C, Chalandon Y, et al. Reconstitution of the immune system after hematopoietic stem cell transplantation in humans. Semin Immunopathol. 2008;30(4):425-37.